eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » Amgen, Inc. - Comment

Amgen, Inc. - Comment

Document ID: FDA-2010-D-0529-0007
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: January 20 2011, at 12:00 AM Eastern Standard Time
Date Posted: January 31 2011, at 12:00 AM Eastern Standard Time
Comment Start Date: October 25 2010, at 12:00 AM Eastern Standard Time
Comment Due Date: January 24 2011, at 11:59 PM Eastern Standard Time
Tracking Number: 80bcf0bd
View Document:  View as format xml

View Comment

We are pleased to have the opportunity to offer comments on the Draft Guidance for Industry on Qualification Process for Drug Development Tools. Comments attached.

Attachments:

Amgen, Inc. - Comment

Title:
Amgen, Inc. - Comment

View Attachment: View as format pdf

Related Comments

    View All
Total: 15
Novo Nordisk Inc. - Comment
Public Submission    Posted: 01/18/2011     ID: FDA-2010-D-0529-0003

Jan 24,2011 11:59 PM ET
Amgen, Inc. - Comment
Public Submission    Posted: 01/31/2011     ID: FDA-2010-D-0529-0007

Jan 24,2011 11:59 PM ET
Bausch+Lomb - Comment
Public Submission    Posted: 01/31/2011     ID: FDA-2010-D-0529-0008

Jan 24,2011 11:59 PM ET
Quintiles - Comment
Public Submission    Posted: 01/31/2011     ID: FDA-2010-D-0529-0009

Jan 24,2011 11:59 PM ET
International Society for CNS Clinical Trials and Methodology (ISCTM) - Comment
Public Submission    Posted: 01/31/2011     ID: FDA-2010-D-0529-0010

Jan 24,2011 11:59 PM ET